Albuterol sulfate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1982
- First approval year
- 1982
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Albuterol sulfate
- Molecular weight
- 576.71
- Structure (SMILES)
- CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.O=S(=O)(O)O
- accuneb
- Accuneb
- albuterol sulfate
- Albuterol sulfate
- albuterol sulfate component of airsupra
- Albuterol sulfate component of airsupra
- albuterol sulfate component of combivent
- Albuterol sulfate component of combivent
- albuterol sulfate component of duoneb
- Albuterol sulfate component of duoneb
- proair
- Proair
- proair digihaler
- Proair digihaler
- proair hfa
- Proair hfa
- proair respiclick
- Proair respiclick
- proventil
- Proventil
- proventil hfa
- Proventil-hfa
- Torpex (albuterol sulfate)
- torpex albuterol sulfate
- ventolin
And 9 more, listed on the interactive page.
- aerolin
- AEROLIN
- airomir
- AIROMIR
- airsupra component albuterol sulfate
- AIRSUPRA COMPONENT ALBUTEROL SULFATE
- albuterol sulfate
- Albuterol sulfate
- ALBUTEROL SULFATE [GREEN BOOK]
- ALBUTEROL SULFATE [MI]
- ALBUTEROL SULFATE [ORANGE BOOK]
- ALBUTEROL SULFATE [USAN]
- ALBUTEROL SULFATE [USP IMPURITY]
- ALBUTEROL SULFATE [USP MONOGRAPH]
- ALBUTEROL SULFATE [USP-RS]
- ALBUTEROL SULFATE [VANDF]
- albuterol sulfate green book
- albuterol sulfate mi
- albuterol sulfate orange book
- albuterol sulfate usan
- albuterol sulfate usp impurity
- albuterol sulfate usp monograph
- albuterol sulfate usp rs
- albuterol sulfate vandf
- albuterol sulphate
And 75 more, listed on the interactive page.
- CAS registry numbers
- 51022-70-9
- ChEMBL ID
- CHEMBL1441059
- InChIKey
- BNPSSFBOAGDEEL-UHFFFAOYSA-N
- RxNorm IDs (RxCUI)
- 142153
- FDA ingredient codes (UNII)
- 021SEF3731
- 39859
- 43834519
- Applicant
- KINDEVA
- Approval date
- 15 Aug 1996
- Application number
- NDA020503
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Drug name stem
- -terol
Administration routes
- Oral
- topical
Mechanisms of action
- Mechanism
- Beta-2 adrenergic receptor agonist
- Action type
- Agonist
- Target
- Beta-2 adrenergic receptor
- Protein identifier
- P07550
Open Targets mechanisms
- Mechanism
- Beta-2 adrenergic receptor agonist
- Action type
- Agonist
- Target
- Beta-2 adrenergic receptor
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Lung Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003818
- Subject identifier
- D008171
- Condition
- Status Asthmaticus
- Highest recorded phase
- 1
- Condition identifier
- EFO:0008590
- Subject identifier
- D013224
- Condition
- Bronchial Spasm
- Highest recorded phase
- 4
- Condition identifier
- HP:4000007
- Subject identifier
- D001986
- Condition
- Asthma
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition
- Asthma, Exercise-Induced
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001250
- Condition
- Bronchial Spasm
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001986
- Condition
- Respiratory Distress Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100130
- Subject identifier
- D012128
- Condition identifier
- EFO_0000319
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000341
- Condition identifier
- EFO_0003818
- Highest recorded phase
- 1
- Condition identifier
- EFO_0008590
- Highest recorded phase
- 1
- Condition identifier
- HP_0030828
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002465
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004784
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004979
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005002
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0006502
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0015796
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0019091
- Condition identifier
- MONDO_0100130
Warnings
- Warning
- Black Box Warning
Open Targets warnings
- Warning
- Black Box Warning
- Country
- United States
- Event
- asthma
- Reports
- 3,143
- Reporting signal score
- 11,040.5
- Event
- asthma-chronic obstructive pulmonary disease overlap syndrome
- Reports
- 39
- Reporting signal score
- 168.568
- Event
- blood calcium decreased
- Reports
- 108
- Reporting signal score
- 190.211
- Event
- blood count abnormal
- Reports
- 811
- Reporting signal score
- 2,760.47
- Event
- blood immunoglobulin e increased
- Reports
- 67
- Reporting signal score
- 188.755
- Event
- blood test abnormal
- Reports
- 183
- Reporting signal score
- 445.072
- Event
- breath sounds abnormal
- Reports
- 124
- Reporting signal score
- 358.931
- Event
- bronchial obstruction
- Reports
- 87
- Reporting signal score
- 308.046
- Event
- bronchial secretion retention
- Reports
- 67
- Reporting signal score
- 263.463
- Event
- bronchial wall thickening
- Reports
- 71
- Reporting signal score
- 298.068
- Event
- bronchiectasis
- Reports
- 187
- Reporting signal score
- 543.664
- Event
- bronchitis
- Reports
- 183
- Reporting signal score
- 139.984
- Event
- bronchopulmonary aspergillosis allergic
- Reports
- 44
- Reporting signal score
- 165.373
- Event
- bronchospasm
- Reports
- 97
- Reporting signal score
- 119.785
- Event
- bronchospasm paradoxical
- Reports
- 31
- Reporting signal score
- 128.388
- Event
- bursitis
- Reports
- 93
- Reporting signal score
- 176.162
- Event
- chest discomfort
- Reports
- 577
- Reporting signal score
- 879.313
- Event
- chest x-ray abnormal
- Reports
- 56
- Reporting signal score
- 131.878
- Event
- chronic obstructive pulmonary disease
- Reports
- 497
- Reporting signal score
- 1,087.56
- Event
- chronic sinusitis
- Reports
- 70
- Reporting signal score
- 186.223
- Event
- coeliac disease
- Reports
- 100
- Reporting signal score
- 246.944
- Event
- cognitive disorder
- Reports
- 153
- Reporting signal score
- 157.313
- Event
- condition aggravated
- Reports
- 394
- Reporting signal score
- 145.98
- Event
- cough
- Reports
- 1,181
- Reporting signal score
- 1,648.93
- Event
- creatinine renal clearance decreased
- Reports
- 108
- Reporting signal score
- 255.38
And 59 more, listed on the interactive page.
- NCT00144846
- NCT00394329
- NCT00634517
- NCT00634829
- NCT00646620
- NCT00667407
- NCT00861926
- NCT01899144
- NCT02126839
- NCT02182713
- NCT02584257
- NCT02969408
- NCT03371459
- NCT03528577
- NCT05035862
- NCT05292976
- NCT05884970
- NCT06154304
- NCT00434993
- NCT00462540
- NCT00665600
- NCT03256695
- NCT03480997
- NCT04606394
- NCT05987371
And 4 more, listed on the interactive page.
- Dose
- 3 mL vial
- Route
- Inhalation
- How often
- 4 times per day, up to 2 additional doses per day if needed
Conditions of use
- Administered via nebulization with a jet nebulizer connected to an air compressor
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 4
- Polar surface area
- 72.72
- Calculated partition coefficient (ALogP)
- 1.31
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 39
- Molecular formula
- C26H44N2O10S
- Monoisotopic mass
- 576.27166678
- Natural product
- No
- 0054-0742
- 0093-3174
- 0173-0682
- 0310-9080
- 0378-7057
- 0378-7058
- 0378-8270
- 0378-9671
- 0487-0201
- 0487-0301
- 0487-9501
- 0487-9901
- 0487-9904
- 0597-0024
- 0781-7296
- 45802-088
- 47335-703
- 47335-756
- 50742-392
- 50742-393
- 51407-367
- 51407-368
- 53489-176
- 53489-177
- 59310-117
And 125 more, listed on the interactive page.
- Recorded assays
- 180
- Active assays
- 1
Active assay types
- Screening
- Bronchodilator Agents
- Tocolytic Agents
- Adrenergic beta-2 Receptor Agonists
Related records
Trials (362)
- (CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)
- 4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
- 4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma
- 5 Versus 10 Units of Insulin in Hyperkalemia Management
- A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma
- A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma
- A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma
- A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma
- A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma
- A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:
- A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics
- A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects
- A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- A Comparative Study of Adding Ipratropium to Salbutamol for the Treatment of Asthma Attack in Children
- A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma
- A Comparison of Combivent UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg)
- A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- A Crossover Study in the Treatment of Patients With COPD
- A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)
Approved for (2)
In development for (5)
- Adult acute respiratory distress syndrome Phase 2
- Allergic asthma Phase 1
- Cardiovascular disorder Phase 1
- Lung disorder Phase 1
- Status asthmaticus Phase 1
Targets (1)
- ADRB2 Beta-2 adrenergic receptor agonist